Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.78 |
| ▸ | DHFR | P00374 | 6/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.50 |
| ▸ | FOLR2 | P14207 | 2/20 | 0.44 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.44 |
| ▸ | GART | P22102 | 2/20 | 0.44 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304727 | 0.86 | MBOAT4 (0.62) | MBOAT4DHFRTYMS | |
| SCHEMBL6305013 | 0.80 | DHFR (1.00) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL8802138 | 0.75 | NAMPT (0.63) | MBOAT4DHFRTYMSFOLR2FOLR1 | |
| SCHEMBL8800454 | 0.75 | MBOAT4 (0.49) | MBOAT4DHFR | |
| SCHEMBL24344120 | 0.74 | DHFR (0.49) | MBOAT4DHFR | |
| SCHEMBL27709073 | 0.73 | MBOAT4 (0.50) | MBOAT4DHFR | |
| SCHEMBL13833595 | 0.72 | DHFR (0.46) | DHFR | |
| SCHEMBL7660756 | 0.72 | P2RX3 (0.47) | MBOAT4DHFR | |
| SCHEMBL13833594 | 0.70 | DHFR (0.47) | DHFR | |
| SCHEMBL2915133 | 0.69 | DHFR (0.46) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2004-02-26 | — | — | US | disclosed |
| US-6696455-B1 | NITROGEN COMPOUNDS SUCH AS 6-CHLORO-2-METHYL-4-OXO-PYRIDO (3,2-D)PYRIMIDINE USED AS ANTICARCINOGENIC AGENTS AND/OR FOR PROPHYLAXIS OF INFECTIONS CAUSED BY PNEUMOCYSTIS OR TOXOPLASMA | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2004-02-24 | — | — | US | disclosed |
| US-20030144509-A1 | Pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2003-07-31 | — | — | US | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| US-6518426-B1 | Novel pyrrolo(3,2-d)pyrimidine derivatives of the following general formula compounds are useful in the treatment of bacterial infections such as Toxoplasmosis gondii and Pneumocystis carinii, and various types of cancer, | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-02-11 | — | — | US | disclosed |
| US-6420370-B1 | ANTITUMOR, ANTIBIOTIC, ANTIMALARIAL, ANTIFUNGAL OR ANTIPROTOZOAL AGENTS, OR AS SYNERGISTIC AGENTS ENZYME INHIBITORS | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-07-16 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
| US-6221872-B1 | DEBROMINATING A PYRROLE; FUSING THE PRODUCT WITH AN AMIDINE; CONDENSING THE PRODUCT WITH A NUCLEOPHILE; REDUCING AND PURIFYING | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2001-04-24 | — | — | US | disclosed |
| US-6103727-A | RESISTING AND TREATING PNEUNOCYSTIS CARINII AND TOXOPLASMOSIS GONDII INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; AUTOMIMMUNE DISEASES; AIDS; ANTICARCINOGENIC,-TUMOR,-PROTAZOA AGENTS; MALARIA; FUNGICIDES; SYNERGISTIC WITH SULFONAMIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096750-A | Furopyrimidines and methods of making and using the same derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-08-01 | — | — | US | disclosed |
| US-6077844-A | FOR TREATING ILLNESSES SUCH AS CANCER, AND SECONDARY INFECTIONS CAUSED BY PNEUMOCYSTIS CARINII AND TOXOPLASMOSIS GONDII IN IMMUNOCOMPROMISED PATIENTS | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0530537-B1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-01-08 | — | — | EP | disclosed |
| US-5403843-A | Pyrrolopyrimidinyalglutaminate derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0530537-A1 | Condensed pyrimidine derivatives, their production and use as antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | MBOAT4 4863/4885DHFR 11/4885TYMS 2/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | MBOAT4 4863/4885DHFR 11/4885TYMS 2/4885 |
| US-20030144509-A1 | Pyrimidine derivatives and methods of making and using these derivatives | TYMS, TYMP, DPYD | MBOAT4 4866/4885DHFR 6/4885TYMS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.